AnaptysBio (ANAB) investor relations material

Executive summary

• Jemperli global net sales reached $644 million for the six months ended June 30, 2026, up 34% year-over-year, with $331 million in Q2 alone, a 26% increase year-over-year.

• Positive interim results from the pivotal AZUR-1 trial for Jemperli in rectal cancer; FDA PDUFA action date set for February 2027, with expedited review eligibility.

• Litigation with GSK and Tesaro held in July; post-trial hearing scheduled for October 2026, with judgement expected in Q4 2026 or Q1 2027.

• Quimilza (imsidolimab) received FDA PDUFA date of December 12, 2026, for GPP and Orphan Designation in the EU.

• Separation from First Tracks Biotherapeutics completed in April 2026; fiscal year-end changed to June 30.

Financial highlights

• Collaboration revenue was $27.5 million for Q2 2026 and $53.0 million for the first half, up from $22.3 million and $50.0 million year-over-year.

• Net income from continuing operations was $177.3 million for Q2 2026 and $176.4 million for the first half, compared to $5.7 million and $16.6 million year-over-year.

• Basic net income per share from continuing operations was $6.06 for Q2 and $6.09 for the first half, up from $0.20 and $0.56 year-over-year.

• Cash, cash equivalents, and investments totaled $164.1 million as of June 30, 2026, down from $211.6 million at year-end 2025.

Outlook and guidance

• Anticipates >$390 million in annualized Jemperli royalties by 2029 at GSK's peak sales guidance of >$2.7 billion.

• Expects paydown of remaining ~$299 million non-recourse debt monetization in the second half of 2027.

• Anticipates FDA approval of Quimilza in GPP in December 2026.